Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market ...